‘AeroNabs’ Promise Powerful, Inhalable Protection Against COVID-19
UCSF scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease.
University of California San Francisco
Give to UCSF
Drug Prevents Multiple Sclerosis Relapses in Phase 3 Trial
A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) – the most common form of the illness, in which symptoms wax and wane.
Some ‘Inert’ Drug Ingredients May Be Biologically Active
Some supposedly inert ingredients in common drugs — such as dyes and preservatives — may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UCSF and the Novartis Institutes for BioMedical Research.
Seeking Immunity Against COVID-19
Joel Ernst, MD, addresses key questions about how vaccine development works and why vaccines are especially important in the case of COVID-19.
COVID-19 Frontliners: A Race for Lifesaving Treatment
Pharmacist Katherine Yang, PharmD, raced to get a new, lifesaving drug approved for emergency treatment of COVID-19.
COVID-19 Frontliners: Confronting a Lethal Disease Unlike Any Before We’d Seen Before
What’s it like – as a clinician, researcher, student, or hospital staffer – to confront a lethal disease unlike any you’ve seen before? In this special series, professionals across UCSF share first-person accounts of COVID-19 that reveal grit, ingenuity, and resolve in the face of fear.
UCSF Alumni Confront COVID-19
We asked on social media for alumni to share their pandemic stories. Here’s a selection of submissions that came in from across the country.
Building Blocks for COVID-19 Antiviral Drugs Identified in Rapid Study
Scientists have identified key chemical building blocks for an eventual antiviral drug against SARS-CoV-2, the virus that causes COVID-19.
Newly Diagnosed COVID-19 Patients Needed for Antibiotic Clinical Trial
The nationwide clinical trial will assess whether the common antibiotic azithromycin can reduce hospitalization stays and death caused by the SARS-CoV-2 virus.
Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies
Under a new agreement, Celgene will further invest in the RAN’s state-of-the-art antibody engineering program to expand target discovery from oncology and immunology to include neurology.
Antiviral Drug Remdesivir Can Help Fight the Coronavirus, But Can Patients Get It?
Amid so little good news, early clinical trial results for the anti-viral drug remdesivir have offered hope. The drug appeared to help patients recover faster, from 15 days to 11 days. But the newest obstacle may be the uncertainty that surrounds how the drug will be distributed to patients.
Microbiome Therapy Protects Against Recurrent Bacterial Vaginosis
A product containing healthy vaginal bacteria has proved effective against recurrent bacterial vaginosis (BV), an extremely common vaginal infection that is associated with preterm birth, HIV infection and problems with in vitro fertilization.
